Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Down 41.3% in December

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) saw a significant decline in short interest in the month of December. As of December 31st, there was short interest totaling 68,730 shares, a decline of 41.3% from the December 15th total of 117,022 shares. Approximately 0.9% of the company’s shares are sold short. Based on an average daily volume of 196,189 shares, the days-to-cover ratio is presently 0.4 days. Based on an average daily volume of 196,189 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.9% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Anebulo Pharmaceuticals in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and an average target price of $3.00.

Anebulo Pharmaceuticals Stock Up 4.8%

Shares of ANEB stock opened at $1.09 on Friday. The firm has a 50 day moving average of $1.84 and a two-hundred day moving average of $2.21. The stock has a market capitalization of $44.78 million, a PE ratio of -4.74 and a beta of -0.81. Anebulo Pharmaceuticals has a 52 week low of $0.90 and a 52 week high of $3.42.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.07. Analysts expect that Anebulo Pharmaceuticals will post -0.52 EPS for the current fiscal year.

Hedge Funds Weigh In On Anebulo Pharmaceuticals

An institutional investor recently bought a new position in Anebulo Pharmaceuticals stock. Goldman Sachs Group Inc. bought a new stake in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 47,954 shares of the company’s stock, valued at approximately $62,000. Goldman Sachs Group Inc. owned approximately 0.12% of Anebulo Pharmaceuticals as of its most recent SEC filing. 28.40% of the stock is currently owned by hedge funds and other institutional investors.

Anebulo Pharmaceuticals Company Profile

Anebulo Pharmaceuticals, Inc (NASDAQ:ANEB) is a clinical‐stage biopharmaceutical company focused on the development of intranasal therapies for the acute treatment of migraine. Its lead product candidate, ANEB-001, is an intranasal formulation of dihydroergotamine mesylate designed to provide rapid relief from migraine attacks while reducing common gastrointestinal side effects associated with oral treatments.

The company is advancing ANEB-001 through pivotal trials in the United States and plans to submit a new drug application to the U.S.